The role of internal limiting membrane peeling in the treatment of diabetic macular edema

Petrachkov D.V.; Budzinskaya M.V.; Arzhukhanov D.D.

doi:https://doi.org/10.17116/oftalma2020136042359

Close metadata

Recommended articles:

Objective structural and functional monitoring of polypeptide retinal neuroprotective therapy in diabetic retinopathy. Russian Annals of Ophthalmology. 2024;(5):97-104

Efficacy of brolucizumab in the treatment of retinal pathologies: a review of post-marketing studies. Russian Annals of Ophthalmology. 2024;(5):154-161

Indirect comparison of anti-angiogenic agents in the treatment of diabetic macular edema. Russian Annals of Ophthalmology. 2024;(6):69-79

Dual inhibition of VEGF-A and angiopoietin-2 in the treatment of neovascular age-related macular degeneration and diabetic macular edema. Russian Annals of Ophthalmology. 2024;(6):100-106

Diabetic retinopathy and pregnancy. Russian Annals of Ophthalmology. 2024;(6):145-151

Angiographic parameters of the retina after various methods of membrane peeling in the treatment of diabetic maculopathy. Russian Annals of Ophthalmology. 2025;(1):37-44

The effect of vitrectomy on changes in molecular biomarker levels of the vitreous cavity in the early postoperative period in proliferative diabetic retinopathy. Russian Annals of Ophthalmology. 2025;(2):30-36

The effects of intraoperative use of angiogenesis inhibitors on outcomes and complication rates in the surgical treatment of proliferative diabetic retinopathy. Russian Annals of Ophthalmology. 2025;(2):44-50

Abstract:

Analysis of the current understanding of the role of internal limiting membrane in the pathogenesis of diabetic macular edema and the feasibility of its surgical removal is based on data from domestic and international literature on pathogenesis, clinical manifestations, outcomes of multicenter studies of treatment and prognosis of this disease. The advantages and disadvantages of both peeling and preservation of the inner limiting membrane are described. The limitations and inconsistencies of data provided by the authors of each theory requires more complete functional studies in the pre- and postoperative periods, increasing the selection of patients, modifying the criteria for inclusion in groups, and microscopic examination of removed membranes. Thus, this issue requires further study due to the ambiguity of the conclusions and the lack of comparative data on the long-term prospects of each of the methods.

Keywords:

diabetic retinopathy

diabetic macular edema

internal limiting membrane

Authors:

Petrachkov D.V.

Research Institute of Eye Diseases

Budzinskaya M.V.

Krasnov Research Institute of Eye Diseases

SPIN RSCI: 3552-7061
Scopus AuthorID: 6508005851
ResearcherID: C-3026-2014
ORCID: 0000-0002-5507-8775

Arzhukhanov D.D.

Research Institute of Eye Diseases

Received:

23.03.2020

Accepted:

26.04.2020

Close metadata

References:

Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol’nym sakharnym diabetom. Pod red.i Dedova I.I., Shestakovoi M.V., Maiorova A.Yu. 9-i vypusk. M.: UP PRINT; 2019. (In Russ.). https://doi.org/10.14341/DM221S1
Virgili G, Menchini F, Murro V, Peluso E, Rosa F, Casazza G. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database of Systematic Reviews. 2011;7: CD008081. https://doi.org/10.1002/14651858.CD008081.pub2
Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H; Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology. 2008; 115(8):1366-1371.e1. https://doi.org/10.1016/j.ophtha.2007.12.004
Chalam KV, Bressler SB, Edwards AR, Berger BB, Bressler NM, Glassman AR, Grover S, Gupta SK, Nielsen JS; Diabetic Retinopathy Clinical Research Network. Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography. Investigative Ophthalmology and Visual Science. 2012;53(13):8154-8161. https://doi.org/10.1167/iovs.12-10290
Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Progress in Retinal and Eye Research. 2003;22:1-29. https://doi.org/10.1016/s1350-9462(02)00043-5
Das A, McGuire PG, Rangasamy S. Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. Ophthalmology. 2015;122(7):1375-1394. https://doi.org/10.1016/j.ophtha.2015.03.024
Rosenblatt A, Udaondo P, Cunha-Vaz J, Sivaprasad S, Bandello F, Lanzetta P, Kodjikian L, Goldstein M, Habot-Wilner Z, Loewenstein A; ARTES Study Group. A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study. Ophthalmology. 2019; 127(3):377-393. https://doi.org/10.1016/j.ophtha.2019.10.005
Korobelnik JF, Do DV, Schmidt-Erfurth U. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247-2254. https://doi.org/10.1016/j.ophtha.2014.05.006
Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625. https://doi.org/10.1016/j.ophtha.2011.01.031
Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema. The 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013-2022. https://doi.org/10.1016/j.ophtha.2013.02.034
Ciulla TA, Bracha P, Pollack J, Williams DF. Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States. Ophthalmology Retina. 2018;2(12):1179-1187. https://doi.org/10.1016/j.oret.2018.06.004
Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10): 1904-1914. https://doi.org/10.1016/j.ophtha.2014.04.024
Bressler SB, Beaulieu WT, Glassman AR. Photocoagulation versus ranibizumab for proliferative diabetic retinopathy: Should Baseline Characteristics Affect Choice of Treatment? Retina. 2019;39(9):1646-1654. https://doi.org/10.1097/IAE.0000000000002377
Chang C-K, Cheng C-K, Bai C-H, Peng C-H, Hu C-C. Development of vitreomacular interface abnormality in patients with diabetic macular edema. Taiwan Journal of Ophthalmology. 2012;2:93-98. https://doi.org/10.1038/eye.2016.317
Ophir A, Martinez MR. Epiretinal membranes and incomplete posterior vitreous detachment in diabetic macular edema, detected by spectral-domain optical coherence tomography. Investigative Ophthalmology and Visual Science. 2011;52(9):6414-6420. https://doi.org/10.1167/iovs.10-6781
Romano MR, Romano V, Vallejo-Garcia JL, Vinciguerra R, Romano M, Cereda M, Angi M, Valldeperas X, Costagliola C, Vinciguerra P. Macular hypotrophy after internal limiting membrane removal for diabetic macular edema. Retina. 2014;34(6):1182-1189. https://doi.org/10.1097/IAE. 0000000000000076
Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, Garretson BR, Trese MT. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. American Journal of Ophthalmology. 2000;130(2):178-186. https://doi.org/10.1016/s0002-9394(00)00472-4
Henrich PB, Monnier CA, Halfter W, Haritoglou C, Strauss RW, Lim RYH, Loparic M. Nanoscale topographic and biomechanical studies of the human internal limiting membrane. Investigative Ophthalmology and Visual Science. 2012;53(6):2561-2570. https://doi.org/10.1167/iovs.11-8502
Sebag J. Age-Related Differences in the Human Vitreoretinal Interface. Archives of Ophthalmology. 1991;109(7):966-971. https://doi.org/10.1001/archopht.1991.01080070078039
Halfter W, Sebag J, Emmet TC. Vitreoretinal Interface and Inner Limiting Membrane. In: Vitreous: In Health and Disease. 2014;21-28. https://doi.org/10.1007/978-1-4939-1086-1_11
Wollensak G, Spoerl E, Wirbelauer C, Pham DT. Influence of indocyanine green staining on the biomechanical strength of porcine internal limiting membrane. Ophthalmologica. 2004;218(4):278-282. https://doi.org/10.1159/000078621
Kenawy N, Wong D, Stappler T, Romano MR, Das RA, Hebbar G, Prime W, Heimann H, Gibran SK, Sheridan CM, Cheung YH, Hiscott PS. Does the presence of an Epiretinal membrane Alter the cleavage plane during internal limiting membrane peeling? Ophthalmology. 2010;117(2):320-323.e1. https://doi.org/10.1016/j.ophtha.2009.07.024
Tien T, Zhang J, Muto T, Kim D, Sarthy VP, Roy S. High glucose induces mitochondrial dysfunction in retinal Müller cells: implications for diabetic retinopathy. Investigative Ophthalmology and Visual Science. 2017;58(7):2915. https://doi.org/10.1167/iovs.16-21355
Zhang Z-H, Liu H-Y, Hernandez-Da Mota SE, Romano MR, Falavarjani KG, Ahmadieh H, Xu X, Liu K. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials. American Journal of Ophthalmology. 2013; 156(1):106-115.e2. https://doi.org/10.1016/j.ajo.2013.02.008
El-Sabagh HA, Abdelghaffar W, Labib AM, Mateo C, Hashem TM, Al-Tamimi DM, Selim AA. Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications. Ophthalmology. 2011;118(4):636-641. https://doi.org/10.1016/j.ophtha. 2010.08.038
Walshe R, Esser P, Wiedemann P, Heimann K. Proliferative retinal diseases: myofibroblasts cause chronic vitreoretinal traction. British Journal of Ophthalmology. 1992;76(9):550-552. https://doi.org/10.1136/bjo.76.9.550
Kuiper EJ, De Smet MD, Van Meurs JC, Tan HS, Tanck MW, Oliver N, van Nieuwenhoven FA, Goldschmeding R, Schlingemann RO. Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Archives of Ophthalmology. 2006;124(10):1457-1462. https://doi.org/10.1001/archopht.124.10.1457
Franklin TJ. Therapeutic approaches to organ fibrosis. The International Journal of Biochemistry and Cell Biology. 1997;29(1):79-89. https://doi.org/10.1016/s1357-2725(96)00121-5
Goldschmeding R, Aten J, Ito Y, Blom I, Rabelink T, Weening JJ. Connective tissue growth factor: just another factor in renal fibrosis? Nephrology, Dialysis, Transplantation. 2000;15(3):296-299. https://doi.org/10.1093/ndt/15.3.296
Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, Takehara K. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. The Journal of Investigative Dermatology. 1995;105(2):280-284. https://doi.org/10.1111/1523-1747.ep12318465
Frank RN. Vascular endothelial growth factor — its role in retinal vascular proliferation. New England Journal of Medicine. 1994;331(22):1519-1520. https://doi.org/10.1056/NEJM199412013312212
Schlingemann RO, Van Hinsbergh VW. Role of vascular permeability factor/vascular endothelial growth factor in eye disease. British Journal of Ophthalmology. 1997;81(6):501-512. https://doi.org/10.1136/bjo.81.6.501
Kuiper EJ, Van Nieuwenhoven FA, de Smet MD. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One. 2008; 3(7):e2675. https://doi.org/10.1371/journal.pone.0002675
Fong DS, Aiello L, Gardner TW, King GL, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, Klein R; American Diabetes Association. Blankenship G, Diabetic retinopathy. Diabetes Care. 2003;26(1):226-229. https://doi.org/10.2337/diacare.26.1.226
Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature. 2005;438(7070):960-966. https://doi.org/10.1038/nature04482
He S, Jin ML, Worpel V, Hinton DR. A role for connective tissue growth factor in the pathogenesis of choroidal neovascularization. Archives of Ophthalmology. 2003;121(9):1283-1288. https://doi.org/10.1001/archopht.121.9.1283
Suzuma K, Naruse K, Suzuma I, Takahara N, Ueki K, Aiello LP, King GL. Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. The Journal of Biological Chemistry. 2000;275(52):40725-40731. https://doi.org/10.1074/jbc.M006509200
Hughes JM, Kuiper EJ, Klaassen I, Canning P, Stitt AW, Van Bezu J, Schalkwijk CG, Van Noorden CJ, Schlingemann RO. Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. Diabetologia. 2007;50(5):1089-1098. https://doi.org/10.1007/s00125-007-0621-4
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine. 1994;331(22):1480-1487. https://doi.org/10.1056/NEJM199412013312203
Kuiper EJ, Hughes JM, Vogels IMC, Goldschmeding R, Van Noorden CJF, Schlingemann RO, Klaassen I. Effect of VEGF-A on expression of pro-fibrotic growth factor and extracellular matrix genes in the retina. Investigative Ophthalmology and Visual Science. 2007;48(9):4267-4276. https://doi.org/10.1167/iovs.06-0804
Watanabe D, Takagi H, Suzuma K, Oh H, Ohashi H, Honda Y. Expression of connective tissue growth factor and its potential role in choroidal neovascularization. Retina. 2005;25(7):911-918. https://doi.org/10.1097/00006982-200510000-00015
Hinton DR, Spee C, He S, Weitz S, Usinger W, LaBree L, Oliver N, Lim JI. Accumulation of NH(2)-terminal fragment of connective tissue growth factor in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Care. 2002;7(3):758-764. https://doi.org/10.2337/diacare.27.3.758
Kuiper EJ, Witmer AN, Klaassen I, Oliver N, Goldschmeding R, Schlingemann RO. Differential expression of connective tissue growth factor in microglia and pericytes in the human diabetic retina. British Journal of Ophthalmology. 2004;88(8):1082-1087. https://doi.org/10.1136/bjo.2003.032045
Balashevich LI, Baiborodov YaV, Gatsu MV. Effectiveness of closed vitrectomy with removal of the internal border membrane of the retina in the treatment of refractory diffuse diabetic macular edema. Oftal’mokhirurgiya. 2007; 4:34-38. (In Russ.).
Díaz-Valverde A, Wu L. To peel or not to peel the internal limiting membrane in idiopathic epiretinal membranes. Retina. 2018;38(suppl 1):5-11. https://doi.org/10.1097/IAE.0000000000001906
Tranos P, Wickham L, Dervenis N. The role of membrane-inner retina adherence in predicting simultaneous internal limiting membrane peeling during idiopathic epiretinal membrane surgery. Eye (London, England). 2017; 31(4):636-642. https://doi.org/10.1038/eye.2016.285
Bikbov MM, Fayzrakhmanov RR, Kalanov MR. Effect of peeling of the internal border membrane on the morphofunctional parameters of the retina in proliferative diabetic retinopathy (preliminary report). Vestnik oftal’mologii. 2018;134(1):63-69. (In Russ.).
Dillinger P, Mester U. Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2004;242(8):630-637. https://doi.org/10.1007/s00417-003-0849-8
Rosenblatt BJ, Shah GK, Sharma S, Bakal J. Pars plana vitrectomy with internal limiting membranectomy for refractory diabetic macular edema without a taut posterior hyaloid. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2005;243(1):20-25. https://doi.org/10.1007/s00417-004-0958-z
Recchia FM, Ruby AJ, Carvalho Recchia CA. Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persistent diabetic macular edema. American Journal of Ophthalmology. 2005;139(3): 447-454. https://doi.org/10.1016/j.ajo.2004.09.076
Stefaniotou M, Aspiotis M, Kalogeropoulos C, Christodoulou A, Psylla M, Ioachim E, et al. Vitrectomy results for diffuse diabetic macular edema with and without inner limiting membrane removal. European Journal of Ophthalmology. 2004;14(2):137-143. https://doi.org/10.1177/112067210401400209
Patel JI, Hykin PG, Schadt M, Luong V, Fitzke F, Gregor ZJ. Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. Retina. 2006;26(1):5-13. https://doi.org/10.1097/00006982-200601000-00002
Mochizuki Y, Hata Y, Enaida H, Yoshiyama K, Miyazaki M, Ueno A, Murata T, Sakamoto T, Kubota T, Ishibashi T. Evaluating adjunctive surgical procedures during vitrectomy for diabetic macular edema. Retina. 2006; 26(2):143-148. https://doi.org/10.1097/00006982-200602000-00003
Kumagai K, Ogino N, Furukawa M, Demizu S, Atsumi K, Kurihara H, Iwaki M, Ishigooka H, Tachi N. Internal limiting membrane peeling in vitreous surgery for diabetic macular edema. Nippon Ganka Gakkai Zasshi. 2002; 106(9):590-594.
Dehghan MH, Salehipour M, Naghib J, Babaeian M, Karimi S, Yaseri M. Pars plana vitrectomy with internal limiting membrane peeling for refractory diffuse diabetic macular edema. Journal of Ophthalmic and Vision Research. 2010;5(3):162-167.
Kimura T, Kiryu J, Nishiwaki H, Oh H, Suzuma K, Watanabe D, Kurimoto M, Takagi H. Efficacy of surgical removal of the internal limiting membrane in diabetic cystoid macular edema. Retina. 2005;25(4):454-461. https://doi.org/10.1097/00006982-200506000-00010
Matsunaga N, Ozeki H, Hirabayashi Y, Shimada S, Ogura Y. Histopathologic evaluation of the internal limiting membrane surgically excised from eyes with diabetic maculopathy. Retina. 2005;25(3):311-316. https://doi.org/10.1097/00006982-200504000-00010
Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno A, Itaya K, Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2002;240(6):423-429. https://doi.org/10.1007/s00417-002-0454-2
Yanyali A, Nohutcu AF, Horozoglu F, Celik E. Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. American Journal of Ophthalmology. 2005;139(5):795-801. https://doi.org/10.1016/j.ajo.2004.12.017
Yamamoto T, Hitani K, Sato Y, Yamashita H, Takeuchi S. Vitrectomy for diabetic macular edema with and without internal limiting membrane removal. Ophthalmologica. 2005;219(4):206-213. https://doi.org/10.1159/000085729
Uemura A, Kanda S, Sakamoto Y, Kita H. Visual field defects after uneventful vitrectomy for epiretinal membrane with indocyanine green-assisted internal limiting membrane peeling. American Journal of Ophthalmology. 2003; 136(2):252-257. https://doi.org/10.1016/s0002-9394(03)00157-0
Haritoglou C, Gass CA, Schaumberger M, Ehrt O, Gandorfer A, Kampik A. Macular changes after peeling of the internal limiting membrane in macular hole surgery. American Journal of Ophthalmology. 2001;132(3):363-368. https://doi.org/10.1016/s0002-9394(01)01093-5
Terasaki H, Miyake Y, Nomura R, Piao CH, Hori K, Niwa T, Kondo M. Focal macular ERGs in eyes after removal of macular ILM during macular hole surgery. Investigative Ophthalmology and Visual Science. 2001;42(1): 229-234.
Kamura Y, Sato Y, Isomae T, Shimada H. Effects of internal limiting membrane peeling in vitrectomy on diabetic cystoid macular edema patients. Japanese Journal of Ophthalmology. 2005;49(4):297-300. https://doi.org/10.1007/s10384-005-0199-7
Gandorfer A, Messmer EM, Ulbig MW, Kampik A. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina. 2000;20(2):126-133.
Tamura T, Hirakata A, Oda H, Outcome of vitreous surgery with internal limiting membrane peeling for diabetic macular edema. Ganka Rinsho Iho. 2003;97:979-982.
Radetzky S, Walter P, Fauser S, Koizumi K, Kirchhof B, Joussen AM. Visual outcome of patients with macular edema after pars plana vitrectomy and indocyanine green-assisted peeling of the internal limiting membrane. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2004;242(4): 273-278. https://doi.org/10.1007/s00417-003-0731-8